Verified April 2026 · Cats first

Is There an Ozempic for Cats?

Short answer: not yet — but cats are the first animals being studied. Two separate feline GLP-1 trials are running right now. Here's what's real.

10 min read·Updated April 26, 2026·By Iacob Pastina

There is no FDA-approved GLP-1 medication — Ozempic, Wegovy, semaglutide, or otherwise — for cats as of April 2026. Veterinarians cannot legally prescribe human GLP-1 medications to cats. But unlike dogs, cats are now first in line: two separate clinical trials testing pet-specific GLP-1 drugs in cats are actively enrolling. Okava Pharmaceuticals' MEOW-1 trial tests an exenatide-releasing implant. Akston Biosciences' AKS-562c tests a once-weekly injection at Cornell University. Both report results in summer 2026.

Why cats first? Three reasons. (1) Feline obesity is reaching crisis levels — APOP's vet survey put US cat overweight/obesity prevalence at 61%, slightly higher than dogs. (2) Cats are notoriously hard to put on diets through food restriction alone — owners report severe behavioral problems and food-aggression when intake drops. A pharmaceutical option fits the species better. (3) Cats don't have the same pancreatitis breed-predisposition pattern as dogs, which lowers one of the regulatory barriers for GLP-1 trials.

If you typed 'Ozempic for cats' because your cat is overweightRead our overweight cat guide for what works today, and join the trial alerts list so you'll know the day pet GLP-1 launches. Don't wait for the trial — start the BCS check and food adjustment now.

What's Actually in Trials Right Now

Okava MEOW-1 — The Exenatide Implant

Okava Pharmaceuticals is developing OKV-119, a small subcutaneous implant designed to release exenatide (a GLP-1 receptor agonist originally approved for human diabetes) over approximately six months. The MEOW-1 trial — Management of Excess Overweight cats With OKV-119 — enrolls at least 50 cats. About two-thirds receive the active implant, the rest serve as controls. Owners observe their cats over a 3-month primary period with an optional 3-month extension. Trial initiation was December 2025; results are expected summer 2026, with FDA submission targeted for 2027-2028 and potential commercial launch around $100/month-equivalent retail pricing if approved.

Akston AKS-562c — The Weekly Injection at Cornell

Separate from Okava, Akston Biosciences is running a feline trial at the Cornell University College of Veterinary Medicine. Their candidate, AKS-562c, is a once-weekly GLP-1 Fc-fusion injection — a different molecule and a different delivery format from Okava's implant. The Cornell trial enrolls 70 cats with the option to expand to 140, over a roughly 3-month observation period. Akston announced trial initiation in November 2025.

These are two separate companies, two separate drugsNews coverage frequently conflates them because both run in cats and both target GLP-1. Okava (OKV-119 implant, MEOW-1 trial) and Akston (AKS-562c weekly injection, Cornell trial) are independent. Different molecules, different delivery formats, different timelines. Both list dogs as the next planned species — neither has announced a canine trial start date.

Realistic Timeline

StageOkava OKV-119Akston AKS-562c
Trial startDecember 2025November 2025
Cats enrolled≥5070 (up to 140)
Primary observation3 months + 3 mo opt~3 months
Results expectedSummer 2026Mid-to-late 2026
FDA submission2027-2028Not announced
Cat market launch2027-2028 (best case)Not announced
Dog trial startNot announcedNot announced
Realistic dog launch2028-20302028-2030

Even in a best-case scenario, no FDA-approved cat GLP-1 will be available before late 2027. Veterinary drug development from Phase 2 to FDA approval typically takes 2-3 years after positive trial readout, and that's assuming the trial succeeds.

Why Vets Won't Prescribe Human Ozempic to Your Cat

  1. Species-specific dosing has never been studied for cats. Human dosing scales by body weight, but GLP-1 receptor density and incretin response differ significantly between species. A 'safe' human dose could be sub-therapeutic — or unsafe — in a cat of any size.
  2. Hepatic lipidosis risk is elevated in cats with rapid weight loss. Cats who lose weight too fast develop fatty liver disease (hepatic lipidosis), which can be fatal. GLP-1 medications cause appetite suppression, and an off-label, untested dose could trigger weight loss faster than the cat's liver can adapt.
  3. Compounding pharmacies cannot legally fill a human-drug prescription for a cat without veterinary oversight, and most veterinarians won't write that script. FDA guidance for veterinary compounding restricts compounding for off-label species use without a clinical justification — and 'my cat is overweight' is not a clinical justification when food therapy is the standard of care.

What You Can Actually Do Right Now

  1. Confirm your cat is actually overweight. Use the 9-point Body Condition Score scale. Most owners overestimate or underestimate by 1-2 BCS points. A cat with BCS 6-7 is overweight; BCS 8-9 is obese.
  2. Switch to a vet-formulated weight management food. Hill's Metabolic, Royal Canin Satiety, and Purina OM all have feline-specific weight loss formulations with reduced calorie density and increased protein/fiber for satiety.
  3. Use a portion-controlled timed feeder. Cats don't self-regulate well with free-feeding. A timed automatic feeder splitting daily intake into 4-5 small meals helps prevent the food-aggression that crash diets cause.
  4. Add play exercise — 10-15 min twice daily. Wand toys, laser pointers, and food puzzles. Cats that play eat less and lose weight more steadily.
  5. Re-weigh monthly, not weekly. Cats should lose 0.5-2% of body weight per week. A 12-pound cat losing 0.5 pound per month is on track. Faster than that risks hepatic lipidosis.

Get Notified When Cat GLP-1 Launches

We track both cat trials and will send one email when the first cat GLP-1 medication becomes commercially available. No spam. No marketing emails. Single-purpose alert.

Frequently Asked Questions

Can I give my cat my Ozempic prescription?+
No. Human Ozempic (semaglutide) is not approved for cats, dosing has never been established for the species, and cats are at risk of hepatic lipidosis with rapid appetite suppression. Veterinarians will not write off-label semaglutide prescriptions for cats.
When will Ozempic for cats be available?+
Two cat-specific GLP-1 drugs are in trials right now. Okava's OKV-119 (MEOW-1 trial) and Akston's AKS-562c (Cornell trial) both report results in summer 2026. FDA approval and commercial launch realistically 2027-2028, assuming successful trials.
How much will pet GLP-1 cost?+
Okava has indicated a ~$100/month-equivalent retail target. Akston has not publicly announced pricing.
What's the difference between Okava and Akston?+
Different companies, different drugs, different delivery formats. Okava's OKV-119 is an exenatide-releasing implant lasting roughly 6 months. Akston's AKS-562c is a once-weekly GLP-1 Fc-fusion injection. Both are in cats, both list dogs as next species, but they're independent programs.

Related

Veterinary disclaimer:This article is for informational purposes only and does not constitute veterinary advice. Always consult a licensed veterinarian before changing your pet's diet, exercise routine, or medication. Information is current as of the publication date but pet pharmaceutical and food formulation details may change.

Looking for human GLP-1 medications instead?

Visit GLP-1 Picks → 42 verified telehealth providers